Comparative analysis of clinicopathological features, PET/CT parameters and efficacy of neoadjuvant therapy in breast cancer with different HER2 expression levels
10.3760/cma.j.cn321828-20240614-00208
- VernacularTitle:不同HER2表达水平乳腺癌的临床病理特征、PET/CT参数及新辅助治疗效果的比较
- Author:
Jie LIU
1
;
Xiaofeng LI
1
;
Wei CHEN
1
Author Information
1. 天津医科大学肿瘤医院分子影像及核医学诊疗科、国家恶性肿瘤临床医学研究中心、天津市肿瘤防治重点实验室、天津市恶性肿瘤临床医学研究中心、乳腺癌防治教育部重点实验室，天津 300060
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neoadjuvant therapy;
Genes, erbB-2;
Positron-emission tomography;
Tomography, X-ray computed
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(6):341-345
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinicopathological features, PET/CT parameters and efficacy of neoadjuvant therapy (NAT) in breast cancer patients with different human epidermal growth factor receptor 2 (HER2) expression levels.Methods:Data of 400 patients with breast cancer (all females, age 50.0(43.0, 58.0) years) who underwent PET/CT examination from May 2014 to June 2023 in Tianjin Medical University Cancer Institute and Hospital were collected retrospectively. All patients were divided into hormone receptor (HR) positive group and HR negative group, and then divided into 3 subgroups defined as HER2-zero expression, HER2-low expression and HER2-over expression. Clinicopathological features, PET/CT parameters and NAT efficacy of patients in different groups were compared. Kruskal-Wallis rank sum test, Bonferroni method, and χ2 test were performed to analyze the data. Results:Among 400 patients, there were 279 patients in HR positive group (69.75%) and 121 in HR negative group (30.25%). In HR positive group, there were 36, 171 and 72 patients in HER2-zero expression, HER2-low expression and HER2-over expression subgroups respectively, which were 27, 39 and 55 in HR negative group, respectively. In HR positive group, Ki-67, pathological complete response (pCR) rate, SUV max, SUV mean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of patients in 3 subgroups were statistically different ( H values: 4.99-13.27, χ2=21.98, all P<0.05). Among them, Ki-67, pCR rate, MTV, SUV max, SUV mean and TLG of patients in HER2-low expression subgroup were lower than those in HER2-over expression subgroup (all P<0.017 (Bonferroni method corrected)). In the HR negative group, Ki-67, pCR rate, SUV max, SUV mean, MTV and TLG of patients in 3 subgroups were also statistically different ( H values: 6.29-26.95, χ2=17.23, all P<0.05). Among them, compared to patients in HER2-over expression subgroup, higher Ki-67 and lower pCR rate of patients in HER2-zero subgroup and HER2-low expression subgroup were found (all P<0.017 (Bonferroni method corrected)). MTV of patients in HER2-low expression subgroup was lower than that in other subgroups, and TLG was also lower than that in HER2-zero expression subgroup (all P<0.017 (Bonferroni method corrected)). Conclusion:Clinicopathological features, PET/CT parameters and NAT efficacy of breast cancer patients with HER2-low expression are different from those with HER2-zero expression and HER2-over expression.
